https://www.streetinsider.com/Analyst+Comments/...o+Buy/15493558.html
am14.05:(nach dem Verfall)
BTIG analyst Sean Lavin upgraded TransEnterix (NYSE: TRXC) from Neutral to Buy with a price target of $3.00.
The analyst comments "TRXC shares have dropped ~40%. While we, like everyone else, were disappointed by the weak result, after discussing the reasons behind the shortfall, we feel these were individual issues at certain hospitals and that there is a chance that next quarter and beyond could be better. We do think there is some added risk now that Intuitive Surgical (ISRG, Neutral) is using leasing to gain customers but still cant see things getting worse near term. The long-term potential for TRXC has not yet been defined, and while it is likely to take several more years to fully understand whether Senhance will see significant adoption or not, we see more upside potential than downside risk at current share prices." |
